» Articles » PMID: 8795137

Loss of an HLA Haplotype in Pancreas Cancer Tissue and Its Corresponding Tumor Derived Cell Line

Overview
Journal Tissue Antigens
Date 1996 May 1
PMID 8795137
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A combination of immunohistochemical, biochemical, and recombinant DNA techniques were used to investigate class I expression in 26 pancreatic adenocarcinomas and 6 autologous tumor-derived cells. The prevalence of HLA losses was found to be comparable to that observed in other tumor types (> 35%), using monomorphic and locus-specific antibodies. In one patient, the original tumor tissue, a tumor derived cell line (IMIM-PC-2), and EBV-transformed lymphocytes were available for study. The patient's phenotype was A25, A30, B18, B18. However, A30 allele product could not be detected in the original tumor not in the cultured tumor cells. In addition, A30 allele could not be isolated from cDNA or genomic clones from the cultured tumor cells whereas it was isolated from the autologous lymphoblastoid cell line. Using isoelectric focusing analysis a significant reduction in the B18 heavy chain product was also observed in the tumor cell line, IMIM-PC-2, suggesting the absence of expression of one allele. Further studies revealed loss of heterozygosity at DR and other loci of chromosome 6 and cytogenetic data strongly suggested deletion of a full chromosome 6. This work indicates for the first time that loss of a full HLA haplotype occurs in tumor tissue and suggests that this mechanism may contribute to the progression of human cancer.

Citing Articles

Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of Class I Alterations in Cancer.

Garrido M, Perea F, Vilchez J, Rodriguez T, Anderson P, Garrido F Cancers (Basel). 2021; 13(20).

PMID: 34680201 PMC: 8534100. DOI: 10.3390/cancers13205046.


The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.

Chang R, Beatty G J Leukoc Biol. 2020; 108(1):363-376.

PMID: 32272502 PMC: 7377219. DOI: 10.1002/JLB.3MIR0320-475R.


Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

Gravett A, Trautwein N, Stevanovic S, Dalgleish A, Copier J Oncoimmunology. 2018; 7(6):e1438107.

PMID: 29930882 PMC: 5990974. DOI: 10.1080/2162402X.2018.1438107.


Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.

Fujii R, Friedman E, Richards J, Tsang K, Heery C, Schlom J Oncotarget. 2016; 7(23):33498-511.

PMID: 27172898 PMC: 5085098. DOI: 10.18632/oncotarget.9256.


Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?.

Hamdi A, Cao K, Poon L, Aung F, Kornblau S, Fernandez Vina M Bone Marrow Transplant. 2015; 50(3):411-3.

PMID: 25621795 PMC: 4807113. DOI: 10.1038/bmt.2014.285.